Clinical trials: Hepatic Neoplasm
Esophageal Neoplasms, Hepatocellular Carcinoma
A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Solid Malignancies
To determine the rate of response and the duration of the response following therapy with Aroplatinin patients with advanced solid malignancies.
- Conditions
- Esophageal Neoplasms, Hepatocellular Carcinoma, Colorectal Neoplasms, Ovarian Neoplasms
- Trial name
- NCT00057395
- Testing
- Aroplatin (Liposomal NDDP, L-NDDP)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Aronex Pharmaceuticals
Hepatocellular Carcinoma
Transarterial Infusion of PD-1 Antibody Plus TACE-HAIC for Unresectable HCC: a Single-arm, Phase 2 Clinical Trial
Hepatocellular carcinoma (HCC) is a common disease in East Asia. Less than 20% of newly diagnosed patients can undergo radical resection.
- Trial name
- AIPD-1 (NCT04814030)
- Testing
- PD-1 inhibitor
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sun Yat-sen University
Hepatic Carcinoma
A Study of Ga-68 Dolacga to Evaluate Liver Reserve Function in Patients With HCC Before and After Proton Therapy
This is a single-center, prospective, open-labeled, single-arm, interventional study to evaluate liver reserve and tumor response using Ga-68 Dolacga positron emission tomography and the safety of the investigational product in…
- Trial name
- NCT06182865
- Testing
- Ga-68 Dolacga Injection
- Where
- Taiwan
- Volunteers
- 10 people
- Sponsor
- National Atomic Research Institute, Taiwan
Carcinoma, Hepatocellular
Dynamic Contrast Enhanced HCC SABR Liver Study
The high dose per fraction (>10Gy/fraction) used in Stereotactic Ablative Body Radiotherapy (SABR) has been shown to be more effective at local tumor control than treatments employing more conventional dose fractions.
- Trial name
- NCT02847767
- Testing
- Perfusion Imaging
- Where
- 2 sites in Canada
- Volunteers
- 20 people
- Sponsor
- British Columbia Cancer Agency
Hepatocellular Carcinoma, Portal Vein Tumor Thrombus
Comprehensive Treatment for Different Types of Tumor Thrombi in the Portal Vein for Hepatocellular Carcinoma Patients
This study is working to evaluate the surgical comprehensive treatment for different types of tumor thrombi in the portal vein for hepatocellular carcinoma patients, to establish a standardized, unified, effective therapeutic…
- Trial name
- NCT00849264
- Testing
- chemotherapy with endostar, treatment with CBP and 5-FU, treatment with endostar, CBP and 5-FU
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Hepatocellular Carcinoma
Interest of Functional MRI (Magnetic Resonance Imagery) (in Patients Suffering From Hepatocellular Carcinoma and Treated With Yttrium
For patients who are suffering from hepatocellular carcinoma and are treated with radioembolization, the purpose of this study is to analyse parameters of functional MRIs that are modified early and to detect parameters that vary…
- Trial name
- ICY (NCT02003339)
- Testing
- Additional RMIs
- Where
- France
- Volunteers
- 25 people
- Sponsor
- Center Eugene Marquis
Hepatocellular Carcinoma, Metastatic Castration Resistant Prostate Cancer
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
This is a phase 1/1b open label, multicenter dose escalation and dose expansion study to investigate the safety, tolerability and anti-tumor activity of TPST-1120, a small molecule selective antagonist of PPARα (peroxisome…
- Conditions
- Hepatocellular Carcinoma, Metastatic Castration Resistant Prostate Cancer, Renal Cell Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT03829436
- Testing
- Part 1 TPST-1120, Part 2 TPST-1120 + nivolumab, Part 3 TPST-1120
- Where
- 11 sites in United States
- Volunteers
- 38 people
- Sponsor
- Tempest Therapeutics
Carcinoma, Hepatocellular
Prompt Or Watchful Monitoring for Hepatitis B Virus Related Hepatocellular Carcinoma Without Elevated viRal Load
Antiviral therapy for HBV may play an important role here, as a large observation study from Taiwan reported that the use of nucleos(t)ide analogues (NUC) was associated with 33% reduction in HCC recurrence.
- Trial name
- POWER (NCT02308319)
- Testing
- Tenofovir disoproxil fumarate
- Volunteers
- 124 people
- Sponsor
- Samsung Medical Center
Hepatocellular Carcinoma
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
The purpose of this study is to determine if tivantinib (ARQ 197) is effective in treating patients with MET diagnostic-high hepatocellular carcinoma (liver cancer) who have already been treated once with another therapy.
- Trial name
- METIV-HCC (NCT01755767)
- Testing
- Tivantinib
- Where
- 112 sites in United States, Argentina and 14 more
- Volunteers
- 383 people
- Sponsor
- Daiichi Sankyo
Locally Advanced Hepatocellular Carcinoma
Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients
This is a multi-national, phase II, parallel-arm, double-blind, placebo-controlled, two-arm study designed to assess the efficacy and safety of SIRT-Y90 followed by atezolizumab plus bevacizumab [study arm], versus SIRT-Y90…
- Trial name
- STRATUM (NCT05377034)
- Testing
- SIRT-Y90 with Atezolizumab + Bevacizumab
- Where
- 14 sites in China, Singapore and 2 more
- Volunteers
- 119 people
- Sponsor
- National Cancer Centre, Singapore
Motor Function, Cognitive Function
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
This study is a postmarketing requirement jointly carried out by four NDA holders (Bayer AG, Bracco, GE Healthcare and Guerbet) and the CRO IQVIA.
- Conditions
- Motor Function, Cognitive Function, Contrast Media
- Trial name
- ODYSSEY (NCT04373564)
- Testing
- Motor Tests, Cognitive Tests, Unenhanced-MRI of the brain
- Where
- 51 sites in United States, Brazil and 6 more
- Volunteers
- 2,076 people
- Sponsor
- Guerbet
HEPATITIS C (HCV), Hepatitis B Virus (HBV)
Community Screening and Management of Hepatitis B, C and Delta in the Mongolian Population Living in France
In Mongolia, mortality from hepatocellular carcinoma (HCC) is one of the highest in the world. Viral hepatitis is the main cause of HCC: the prevalence of hepatitis B (HBV) estimated at 11% In Mongolia, hepatitis C (HCV) at 8.5%…
- Conditions
- HEPATITIS C (HCV), Hepatitis B Virus (HBV), Hepatitis D, Hepatocellular Carcinoma (HCC)
- Trial name
- Mondelta (NCT07038863)
- Testing
- Community screening for hepatitis B, C and delta in the Mongolian population living in France
- Where
- 11 sites in France
- Volunteers
- 2,000 people
- Sponsor
- Hospices Civils de Lyon
Hepatocellular Carcinoma
Emulsion Versus Suspension in Chemoembolization for Hepatocellular Carcinoma
The aim of the study was to evaluate the safety and efficacy of using the new formulation (Lipiodol-cisplatin suspension) for TACE in the treatment of HCC as compared to the conventional formulation (Lipiodol-cisplatin emulsion).
- Trial name
- NCT03268499
- Testing
- Lipiodol-based transarterial chemoembolization
- Where
- Hong Kong
- Volunteers
- 80 people
- Sponsor
- Chinese University of Hong Kong
Liver Cancer
Sorafenib Tosylate and Chemoembolization With Doxorubicin Hydrochloride and Mitomycin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
RATIONALE: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT01011010
- Testing
- doxorubicin hydrochloride, mitomycin C, sorafenib tosylate
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Liver Cancer
Examinations of Tissue From Ablated Malignant Liver Metastases as Predictors of Outcome
The purpose of this study is to see if the investigators can do some tests on tissue from the area of the ablation. The investigators want to know if a test can help predict whether the ablation worked.
- Trial name
- NCT01494324
- Testing
- CT guided percutaneous ablation
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hepatocellular Carcinoma, Liver Disease
An Analysis of Urinary Proteases as Biomarkers for Hepatocellular Carcinoma-101423
Specific urine proteases or groups of these enzymes can be reliable biomarkers and an effective gauge of response to therapy in patients with hepatocellular carcinoma.
- Trial name
- NCT01316679
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Liver Cancer
Pre-procedure Planning for Radiofrequency Ablation Using CT or MR/US Fusion
The purpose of this study is to determine whether fusion technique of pre-radiofrequency ablation (RFA) cross-sectional imaging (CT or MR) and real-time ultrasonography would improve feasibility of RFA in patients with liver…
- Trial name
- NCT02687113
- Testing
- CT/US fusion
- Where
- South Korea
- Volunteers
- 240 people
- Sponsor
- Seoul National University Hospital
Liver Cancer, Hepatocellular Carcinoma
Proton Beam Therapy for Treatment of Hepatocellular Carcinoma
This study is designed to evaluate the possible benefits and side effects of the use of proton therapy for patients with hepatocellular carcinoma.
- Trial name
- NCT00614913
- Testing
- Proton radiation therapy
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Loma Linda University
Advanced Solid Tumors
A Pharmacokinetic Study of Erlotinib in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic Function
This is a multicenter, open-label, 2-arm study comparing erlotinib exposure in cancer patients with adequate hepatic function versus cancer patients with moderate hepatic impairment.
- Trial name
- NCT00139620
- Testing
- Tarceva, erlotinib, OSI-774
- Where
- 5 sites in United States, United Kingdom
- Volunteers
- 39 people
- Sponsor
- OSI Pharmaceuticals
Hepatocellular Carcinoma
Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma
This study will evaluate efficacy and safety of Toripalimab Injection (JS001) with or without Lenvatinib as a Neoadjuvant Therapy in patients with Resectable Hepatocellular Carcinoma (HCC)
- Trial name
- NCT03867370
- Testing
- Toripalimab (JS001 ), Toripalimab (JS001 ) Lenvatinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.